comparemela.com

Page 6 - Mc Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa

VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoreceptor target cells in retinitis .

United statesVigeneron gmbKatarina stinglShaun brown juliaMc servicesOrphan drug designationGeneron gmbhHereditary retinal degenerationsRare eye diseasesPrincipal investigatorDrug designationRetinitis pigmentosa

AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock

With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden .

Bruxelles capitaleStephan witteRichard jonesEva bauer juliaPeter pickkersWorld health organizationRadboud centerDrug administrationDepartment of intensive care medicineMc servicesFast trackAccelerated approvalPriority reviewIntensive care medicineInfectious diseases

Mainz Biomed Reports Full Year 2023 Financial Results

Issuer: Mainz BioMed N.V. / Key word: Annual Results Mainz Biomed Reports Full Year 2023 Financial Results 09.04.2024 / 14:01 CET/CEST The issuer is solely responsible.

United statesUnited kingdomHershel berryAnne hennecke caroline bergmannGuido baechlerColofuture europeMainz biomedJay wohlgemuthEuropean oncology labUs preventive services taskBlueprint life science groupHealth advisorsWorld cancer research fund internationalQuest diagnosticsMc servicesMainz biomed reports full year

EQS-News: Mainz Biomed Reports Full Year 2023 Financial Results

Issuer: Mainz Biomed N.V. / Key word(s): Annual Results Mainz Biomed Reports Full Year 2023 Financial Results 09.04.2.

United statesUnited kingdomGuido baechlerJay wohlgemuthAnne hennecke caroline bergmannHershel berryColofuture europeMainz biomedHealth advisorsQuest diagnosticsBlueprint life science groupMc servicesUs preventive services taskWorld cancer research fund internationalEuropean oncology labMainz biomed reports full year

Data from Newron s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) -April 08, 2024 at 01:02 am EDT

EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Study results Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual.

Kyongsang buktoSouth koreaSri lankaUnited statesUnited kingdomUnited arab emiratesStefan weberAnne hennecke caroline bergmannValentin handschinPaul saganSchizophrenia international research societyEuropean unionMc servicesSupernus pharmaceuticalsNewron pharmaceuticalsNegative syndrome scale

vimarsana © 2020. All Rights Reserved.